NovoCure (NSDQ:NVCR) said today that it applied for a supplemental pre-market approval from the FDA for the 2nd generation of its Optune device for treating glioblastoma, a form of brain cancer. The FDA approved Optune’s 1st iteration in April 2011. It’s a mobile device that delivers low-intensity, intermediate frequency, alternating electric fields, referred to as “tumor treating fields,” […]
NovoCure
NovoCure touts JAMA publication of Optune trial data
NovoCure (NSDQ:NVCR) said today data from the pivotal phase 3 trial of its Optune device, in combination with standard-of-care temozolomide, for treating newly diagnosed glioblastoma has been published in the Journal of the American Medical Association. The results from the EF-14 trial reported that Optune along with temozolomide significantly extended progression-free survival and overall survival compared […]
Novocure touts preliminary data on tumor treating fields
NovoCure (NSDQ:NVCR) said yesterday that a retrospective analysis of its Tumor Treating Fields therapy showed it safe in adult glioblastoma patients with implanted non-programmable shunts. The FDA removed a pre-existing contraindication in October based on the safety data that contraindicated the therapy for patients with non-programmable shunts, Novocure said. The data was presented last month at […]
NovoCure’s cancer therapy effective in late-stage study
(Reuters) — NovoCure (NSDQ:NVCR) said its lead cancer therapy improved survival rate in brain cancer patients in combination with Avastin in a late-stage study, sending its shares up 23% in extended trading. NovoCure’s therapy, Optune, which was evaluated in combination with Roche Holding AG’s cancer drug, reduced the risk of death by 39% in patients, compared with […]
NovoCure raises $158m in IPO
NovoCure (NSDQ:NVCR) yesterday said it raised $158 million from its initial public offering, after the flotation’s underwriters picked up part of an over-allotment option. NovoCure, which is based in St. Helier, Jersey, an island in the English Channel, makes a tumor-zapping device called Optune. Earlier this month the company won expanded indications from the FDA and a new […]
NovoCure wins expanded indications for Optune brain tumor-zapping device
NovoCure said it won expanded indications from the FDA and a new CE Mark indication in the European Union for its brain-tumor treating Optune device. The Optune device uses NovoCure’s “tumor treating fields,” which use low-intensity, intermediate-frequency alternating electric fields that limit cancer cell replication and kill cancer cells, the St. Helier, N.J.-based company said. […]
NovoCure prices $165m IPO
NovoCure priced its initial public offering today, saying it looks to raise $165 million by floating 7.5 million shares at $22 a piece. The company said it is also offering a 30-day underwriters option for an additional 1.1 million shares. NovoCure shares are slated to trade on the NASDAQ Global Select Market under the symbol “NVCR”. Last […]
NovoCure sets terms on $206m IPO
NovoCure today set the terms on its forthcoming initial public offering, saying it expects to float 7.5 million shares at $26 to $29 apiece, or $206.3 million at the midpoint of the range. NovoCure said it expects to net about $189 million from the offering, which includes an underwriters allotment for another nearly 1.9 million shares. Earlier this […]
NovoCure files for $300m IPO
NovoCure registered for an initial public offering that could fetch as much as $300 million for its tumor-zapping Optune brain cancer treatment as it awaits a decision from the FDA on a new indication for the device. The federal safety watchdog granted pre-market approval for Optune in April 2011 for adult patients with glioblastoma whose cancer recurred after […]
MassDevice.com +3 | The top 3 med-tech stories for June 4, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Treating brain cancer with electrical fields : “We’re bringing something completely new”
When Novocure won FDA approval for its Tumor Targeting Field cancer therapy system, the company introduced the oncology world to an entire new modality for treatment.
Cancer patients today are most famliar with surgery, radiation and chemotherapy as thearpy optoins, but certain patients can also opt for Novocure’s non-invasive electromagnetic therapy, which promises to stop cancer cells in their tracks without adding a new suite of side effects.